Literature DB >> 32761859

Determination of the inhibition profiles of pyrazolyl-thiazole derivatives against aldose reductase and α-glycosidase and molecular docking studies.

Yeliz Demir1, Parham Taslimi2, Ümit M Koçyiğit3, Musa Akkuş4, Muhammet Serhat Özaslan1, Hatice Esra Duran5, Yakup Budak6, Burak Tüzün7, Meliha B Gürdere6, Mustafa Ceylan6, Seyithan Taysi8, İlhami Gülçin4, Şükrü Beydemir9,10.   

Abstract

Aldose reductase (AR) is the first and rate-limiting enzyme of the polyol pathway, which converts glucose to sorbitol in an NADPH-dependent reaction. α-Glycosidase breaks down starch and disaccharides to glucose. Hence, inhibition of these enzymes can be regarded a considerable approach in the treatment of diabetic complications. AR was purified from sheep liver using simple chromatographic methods. The inhibitory effects of pyrazolyl-thiazoles ((3aR,4S,7R,7aS)-2-(4-{1-[4-(4-bromophenyl)thiazol-2-yl]-5-(aryl)-4,5-dihydro-1H-pyrazol-3-yl}phenyl)-3a,4,7,7a-tetrahydro-1H-4,7-methanoisoindole-1,3(2H)-dione derivatives; 3a-i) on AR and α-glycosidase enzymes were investigated. All compounds showed a good inhibitory action against AR and α-glycosidase. Among these compounds, compound 3d exhibited the best inhibition profiles against AR, with a Ki value of 7.09 ± 0.19 µM, whereas compound 3e showed the lowest inhibition effects, with a Ki value of 21.89 ± 1.87 µM. Also, all compounds showed efficient inhibition profiles against α-glycosidase, with Ki values in the range of 0.43 ± 0.06 to 2.30 ± 0.48 µM, whereas the Ki value of acarbose was 12.60 ± 0.78 µM. Lastly, molecular modeling approaches were implemented to predict the binding affinities of compounds against AR and α-glycosidase. In addition, the ADME analysis of the molecules was performed.
© 2020 Deutsche Pharmazeutische Gesellschaft.

Entities:  

Keywords:  aldose reductase; enzyme inhibition; molecular docking; pyrazolyl-thiazole; α-glycosidase

Mesh:

Substances:

Year:  2020        PMID: 32761859     DOI: 10.1002/ardp.202000118

Source DB:  PubMed          Journal:  Arch Pharm (Weinheim)        ISSN: 0365-6233            Impact factor:   3.751


  5 in total

Review 1.  Thiazole Ring-A Biologically Active Scaffold.

Authors:  Anthi Petrou; Maria Fesatidou; Athina Geronikaki
Journal:  Molecules       Date:  2021-05-25       Impact factor: 4.411

2.  Exploring synthetic and therapeutic prospects of new thiazoline derivatives as aldose reductase (ALR2) inhibitors.

Authors:  Muhammad Tariq Shehzad; Aqeel Imran; Abdul Hameed; Mariya Al Rashida; Marium Bibi; Maliha Uroos; Asnuzilawati Asari; Shafia Iftikhar; Habsah Mohamad; Muhammad Nawaz Tahir; Zahid Shafiq; Jamshed Iqbal
Journal:  RSC Adv       Date:  2021-05-11       Impact factor: 3.361

Review 3.  Aldose Reductase: An Emerging Target for Development of Interventions for Diabetic Cardiovascular Complications.

Authors:  Sravya Jannapureddy; Mira Sharma; Gautham Yepuri; Ann Marie Schmidt; Ravichandran Ramasamy
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-11       Impact factor: 5.555

Review 4.  Physiological and Pathological Roles of Aldose Reductase.

Authors:  Mahavir Singh; Aniruddh Kapoor; Aruni Bhatnagar
Journal:  Metabolites       Date:  2021-09-27

5.  Potential Molecular Mechanism of Yishen Capsule in the Treatment of Diabetic Nephropathy Based on Network Pharmacology and Molecular Docking.

Authors:  Yaling Hu; Shuang Liu; Wenyuan Liu; Ziyuan Zhang; Yuxiang Liu; Sufen Li; Dalin Sun; Guang Zhang; Jingai Fang
Journal:  Diabetes Metab Syndr Obes       Date:  2022-03-29       Impact factor: 3.168

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.